circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== Ceramics == Vitrification is the progressive partial fusion of a clay, or of a body, as a result of a firing process. As vitrification proceeds, the proportion of glassy bond increases and the apparent porosity of the fired product becomes progressively lower. Vitreous bodies have open porosity, and may be either opaque or translucent. In this context, "zero porosity" may be defined as less than 1% water absorption. However, various standard procedures define the conditions of water absorption. An example is by ASTM, who state "The term vitreous generally signifies less than 0.5% absorption, except for floor and wall tile and low-voltage electrical insulators, which are considered vitreous up to 3% water absorption." Pottery can be made impermeable to water by glazing or by vitrification. Porcelain, bone china, and sanitaryware are examples of vitrified pottery, and are impermeable even without glaze. Stoneware may be vitrified or semi-vitrified; the latter type would not be impermeable without glaze.
=== European Union === In November, Castillo met with Josep Borrell, high representative of the European Union (EU), where Castillo highlighted the solid relationship between Peru and the EU, expressing his "firm will not only to deepen our ties with the European Union, but also to attract European investment for the development of Peru's immense potential". Borrell, meanwhile, expressed the EU's support for Castillo's legitimacy. In October 2022, the Peruvian foreign minister signed in Brussels an EU-Peru Memorandum of Understanding and a Framework Participation Agreement for Peru's participation in crisis management missions and operations, whether military or civilian, organized by the EU. In this way, the Peruvian armed forces and the police would participate voluntarily in such EU operations. In addition, the EU announced a contribution of 14 million euros to Peru for the ecological transition of the Andean country.
Pinealon, also known as EDR peptide, is a synthetic tripeptide of sequence (Glu-Asp-Arg) and purported geroprotector documented in the Russian scientific literature. Pinealon is one of several tripeptide "bioregulators" developed in Russia.
Sources: en.wikipedia.org
== Classification and composition == The meteorite belongs to the CM group of carbonaceous chondrites. Like most CM chondrites, Murchison is petrologic type 2, which means that it experienced extensive alteration by water-rich fluids on its parent body before falling to Earth. CM chondrites, together with the CI group, are rich in carbon and are among the most chemically primitive meteorites. Like other CM chondrites, Murchison contains abundant calcium-aluminium-rich inclusions. More than 15 amino acids, some of the basic components of life, have been identified during multiple studies of this meteorite.
=== Filming continued === Much of the Mobile footage shot by Malmuth was scrapped, although a few local landmarks remain visible in the finished film, such as the Bankhead Tunnel. Filming resumed on July 5. Baxley indicated that he wanted to add two weeks to the schedule and reshoot most of the Mobile scenes to set the entire film on the Gulf Coast. Bosworth claimed to have been told that his family scenes would be included, only to see that option abandoned after production ran out of money, having burnt $4 million of a projected $8 million budget on the discarded material. Bosworth, Henrisksen and Forsythe rewrote some or much of their lines, often on the day of filming. As a result of this unexpected freedom, Henriksen remembered the movie as a particularly enjoyable experience despite its overall travails. The Sheer Yachts boatyard in Ocean Springs was transformed to recreate the Brotherhood's hangout, and host a few ancillary scenes. Bosworth suffered a knee injury at the location on July 11, but did not miss any days. Bosworth performed a higher-than-average share of his stunts, including driving his bike during select action sequences. Baxley's father Paul served as stunt coordinator on the film.
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.